The U.S. Food and Drug Administration will make public reviews of all data and information regarding the emergency use authorization (EUA) granted to Covid-19 drugs and vaccines.
Novartis won FDA approval for a long-delayed version of Amgen’s $4 billion seller Neulasta drug, helping the Swiss drugmaker in an uphill battle to sell copies of rivals’ blockbusters in the U.S.
Danish drugmaker Novo Nordisk is aiming for a big slice of the multibillion-dollar diabetes market with a new pill approved by U.S. authorities that caters for patients with an aversion to needles.
The U.S. FDA issued a new draft guidance for drugmakers aiming their resources at Fabry disease, a rare genetic disease.
The House Appropriations Committee proposed a 2020 draft fiscal year funding bill. The FDA would receive a 6 percent increase in discretionary funding over 2019, amounting to a $184 million bump.
Boosts in R&D Spending Drive Biotech Innovation
21st Century Cures Act, Biologicals, Biotech, Diagnostics, Genetic Diseases, IDMP (Identification of Medicinal Products), Innovation, Investments, Medical Breakthroughs, Medicare Access and CHIP Authorization Act (MACRA), Nasdaq Biotech Index, R&D, Tufts Center for the Study of Drug DevelopmentFueled by a desire for innovation and new medical breakthroughs, the biotech industry continues to enjoy substantial growth due to increased investment in R&D.